60
Participants
Start Date
December 31, 1998
Primary Completion Date
May 31, 2006
Study Completion Date
May 31, 2006
leflunomide
Memorial Sloan-Kettering Cancer Center, New York
New York Neurological Institute, New York
Albert Einstein Comprehensive Cancer Center, The Bronx
Cancer Center of Albany Medical Center, Albany
Western Pennsylvania Cancer Institute, Pittsburgh
Mount Sinai Comprehensive Cancer Center, Miami Beach
Arthur G. James Cancer Hospital - Ohio State University, Columbus
Barrett Cancer Center, The University Hospital, Cincinnati
Henry Ford Hospital, Detroit
University of Iowa College of Medicine, Iowa City
Medical College of Wisconsin, Milwaukee
Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago
University of Texas - MD Anderson Cancer Center, Houston
University of Colorado Cancer Center, Denver
St. Joseph's Hospital and Medical Center, Phoenix
USC/Norris Comprehensive Cancer Center, Los Angeles
Indiana University Cancer Center, Indianapolis
Beth Israel Deaconess Medical Center, Boston
University of Michigan Comprehensive Cancer Center, Ann Arbor
Lineberger Comprehensive Cancer Center, UNC, Chapel Hill
Rhode Island Hospital, Providence
Simmons Cancer Center - Dallas, Dallas
Cross Cancer Institute, Edmonton
British Columbia Cancer Agency, Vancouver
Cancer Care Ontario-London Regional Cancer Centre, London
Princess Margaret Hospital, Toronto
Lead Sponsor
National Cancer Institute (NCI)
NIH
Pfizer
INDUSTRY